AN2 Therapeutics announces $40M private placement of common stock and pre-funded warrants

AN2 Therapeutics, Inc.

Gross proceeds ~$40M from sale of 8.25M shares at $2.85/share and 5.79M pre-funded warrants at $2.84999/warrant.
Investors include Coastlands Capital, Commodore Capital, Vivo Capital; Leerink Partners as placement agent.
Pre-funded warrants have $0.00001 exercise price, exercisable immediately, subject to 9.99% beneficial ownership blocker.
Closing expected March 10, 2026; resale registration statement to be filed within 30 days after closing.
Net proceeds for general corporate purposes and working capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AN2 Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $40 million (effective 2026-03-08).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: approximately $40 million
Effective: 2026-03-08

Exact text from the filing

On March 8, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”).

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-099169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.